Innovative medicines for cancer treatment

Recepta Biopharma

Recepta Biopharma

Biotechnology pro life

Recepta Biopharma (ReceptaBio) is a Brazilian biotechnology company dedicated to the research and development of new drugs for the treatment of cancer. Recepta was founded in 2006 as a result of a partnership of Brazilian businessmen with Ludwig Cancer Research (LCR) Institute, sharing the view that Brazil offers a significant set of competitive advantages for the development of biotechnology focused on human health.

01. Monoclonal Antibodies

Generation of lines and development of monoclonal antibodies for clinical use in the treatment of several types of cancer, including pre-clinical and clinical tests. In particular, ReceptaBio is developing two state-of-the-art immunomodulatory antibodies.

02. Peptides

Discovery and research of peptides with potential for clinical use in the treatment of cancer, as verified in pre-clinical in vitro and in vivo tests.

Cancer

Cancer

A new therapeutic option

Cancer is the second leading cause of death worldwide and will account for 9.6 million deaths in 2018. Globally, nearly 1 in 6 deaths is due to cancer. Approximately 70% of deaths by cancer occur in low- and medium-income countries. In Brazil, the estimate for 2018 is of nearly 600 thousand new cases of cancer (Instituto Nacional do Câncer - INCA). Unlike heart disease, cancer survival rates have not improved significantly in the past 50 years. Thus, cancer continues to pose a challenge to medical science.
Learn more...

14 million

Each year, over 14 million people are diagnosed with cancer worldwide

9,6 million

Cancer is the 2nd leading cause of death worldwide and will account for 9.6 million deaths in 2018

600 thousand

Brazil must have 600,000 new cancer cases per year in 2018-2019 biennium

ReceptaBio Products

ReceptaBio Products

Innovation for cancer treatment

The development of monoclonal antibodies and peptides, such as diagnostic or therapeutic agents, involves several research stages, among them preclinical studies and clinical trials. Browse our portfolio by clicking on the product names to learn more about each biopharmaceutical product.

ProgramPartnerssDiscoveryPre-Clinical DevelopmentPhase I/II
Modulator Checkpoint RebmAb700 • Agenus Inc.

ANTI-PD-1

RebmAb600 • Agenus Inc.

ANTI-CTLA-4

Conjugated antibody-drug RebmAb200 • Mersana Therapeutics

Monoclonal antibody RebmAb100 • University of São Paulo (USP) Medical School
• Ludwig Cancer Research (LCR) Institute

RebmAb300 • University of São Paulo (USP) Medical School
• Ludwig Cancer Research (LCR) Institute

RebmAb400 • University of São Paulo (USP) Medical School
• Ludwig Cancer Research (LCR) Institute

Peptide Rb9 • University of São Paulo (USP) Medical School
• São Paulo State Federal University – UNIFESP

Top